- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Scott Gottlieb, MD: The ACA and the BPCIA
Scott Gottlieb, MD, former commissioner of the FDA, discusses what might become of the Biologics Price Competition and Innovation Act (BPCIA) if the Affordable Care Act (ACA) is invalidated.
Transcript
We’ll see what the courts ultimately do. I’m pretty confident that Congress would continue to authorize the biosimilar pathway, and if for some reason the Affordable Care Act was struck—which doesn’t seem likely—but if for some reason it was struck, I think Congress would come back in and quickly reauthorize the biosimilar pathway.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
